A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG study
Titel:
A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG study
Auteur:
Andersen, J. Andersson, M. Andersen, K.W. Dombemowsky, P. Mouridsen, H.T. Rose, C. Kjaer, M. Gadeberg, C. Hirsch, F.R. Moeller, A.